ReviewNatural product reports2026
Natural products shape microbial ecology and disease in the cystic fibrosis airway.
Review in Natural product reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Covering up to 2026Cystic fibrosis (CF) is a life-shortening autosomal recessive genetic disorder caused by mutation in the gene encoding the CF transmembrane conductance regulator (CFTR). Dysfunction in CFTR leads to the accumulation of thick and dehydrated mucus in the respiratory tract, which serves as a substrate for a complex microbiota that includes commensal oral and respiratory bacteria and opportunistic pathogenic bacteria and fungi. During chronic infections, these microbes persist in the airways and contribute to progressive lung tissue damage, ultimately leading to respiratory failure and premature death. Within this environment, microbes synthesize a diverse repertoire of natural products, including antimicrobials, siderophores and other metallophores, signaling molecules, toxins, and other virulence factors. In this review, we thoroughly discuss natural products produced by members of the CF airway microbiota, primarily the bacterial pathogens
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.